SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer

Khongkow, Mattaka; Olmos, Yolanda; Gong, Chun; Gomes, Ana R.; Monteiro, Lara J.; Yaguee, Ernesto; Cavaco, Tania B.; Khongkow, Pasarat; Man, Ellen P. S.; Laohasinnarong, Sasiwan; Koo, Chuay-Yeng; Harada-Shoji, Narumi; Tsang, Janice W. -H.; Coombes, R. Charles; Schwer, Bjoern; et. al.


In this study, we report the identification of a novel role of SIRT6 in both epirubicin and paclitaxel resistance in breast cancer. We found that SIRT6 protein levels are elevated in paclitaxel- and epirubicin-resistant MCF-7 cells compared with the parental sensitive cells. SIRT6 knockout and depletion sensitized cells to both paclitaxel and epirubicin treatment, whereas SIRT6 ectopic overexpression led to increased resistance to paclitaxel and epirubicin. Moreover, our data suggest that SIRT6 could be mediating epirubicin resistance through enhancing the DNA repair response to epirubicin-induced DNA damage. Clonogenic assays also revealed that mouse embryonic fibroblasts (MEFs) lacking SIRT6 have decreased long-term viability in response to epirubicin. The tumour suppressor FOXO3a increases its levels of acetylation in MEFs depleted of SIRT6, whereas its induction by epirubicin is attenuated in breast cancer cells overexpressing SIRT6. Further cell viability studies demonstrate that deletion of FOXO1/3/4 in MEFs can confer sensitivity to both paclitaxel and epirubicin, suggesting that SIRT6 reduces paclitaxel and epirubicin sensitivity, at least in part, through modulating FOXO acetylation and expression. Consistently, immunohistochemical analysis of 118 breast cancer patient samples revealed that high SIRT6 nuclear staining is significantly associated with poorer overall survival (P 0.018; KaplanMeier analysis). Multivariate Cox analysis demonstrated that nuclear SIRT6 staining remained associated with death after correcting for tumour stage and lymph-node involvement (P 0.033). Collectively, our data suggest that SIRT6 has a role in paclitaxel and epirubicin sensitivity via targeting FOXO proteins and that SIRT6 could be a useful biomarker and therapeutic target for paclitaxel- and epirubicin-resistant cancer.

Más información

Título según WOS: ID WOS:000321753000008 Not found in local WOS DB
Título de la Revista: CARCINOGENESIS
Volumen: 34
Número: 7
Fecha de publicación: 2013
Página de inicio: 1476
Página final: 1486


Notas: ISI